Excellence in clinical research from A to Z

Scroll down ⇩

About us

AtoZ-CRO GmbH is a full-service clinical research organisation (CRO) located in Overath near Cologne, Germany, with over 30 years of experience in clinical development and clinical study management. As a specialist for Germany, Europe, the US, and India, AtoZ-CRO offers a broad range of professional services and partner solutions for international clinical studies with pharmaceuticals and medical devices.


From its head office located in Overath, Germany, AtoZ-CRO manages and coordinates clinical studies of phase 0 through phase IV for national and international clients. The company forms a team of 35 highly experienced and dedicated industry professionals and medical specialists ensuring high standards in clinical study management. AtoZ-CRO is affiliated with a leading initiator of phase I studies in Warsaw, Poland.


Based on the company’s long-established international experience in clinical trial management and cooperation with high-rated business partners, AtoZ-CRO is proud to offer a broad range of services covering all clinical research needs, in particular for small and mid-sized pharmaceutical, biotech, and medical device companies.

Clinical Studies 

Contact us

Clinical Studies

Clinical Studies Phases 0 – IV

  • Planning of clinical studies
  • Preparation of study protocols
  • Design and implementation of CRFs (case report forms) and eCRFs
  • Processing of applications for ethical votes and permissions (e.g. CTA, IND)
  • Regulatory affairs issues
  • Legal EU representative

Other services

  • Monitoring
  • Post-marketing studies

-  NIS

-  PASS

-  Epidemiology

  • Pharmacovigilance
  • Biometry
  • Medical Writing and Translations

About us

Contact us

Contact us

AtoZ-CRO GmbH

Hauptstr. 77
51491 Overath
Tel: 02206 95 99 0
Fax: 02206 820 63
Email: info@atoz-cro.de
www.atoz-cro.de

Business Development

Alexa Foltin-Mertgen, M.Sc.
Email: a.foltin-mertgen@atoz-cro.de

Back to top ⇧

Go to article: Home | The power of patientsGo to article: Scandinavian Health Company InsightGo to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: NSFGo to article: ContentsGo to article: CapsugelGo to article: Capsugel Company Insight Go to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: Molnar Company InsightGo to article: Molnar-InstituteGo to article: A costly oversight: the ongoing impact of the valsartan recallGo to article: Novo Nordisk Company InsightGo to article: Novo NordiskGo to article: Where is the UK’s supply of Migraleve?Go to article: Dupont PharmaceuticalsGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Charting the life and times of the EMA as it leaves LondonGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: CBD: the myth, the magic and the real deal drugsGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: In the age of AMR, does a nationalised drug company make sense? The case for and againstGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: How do cancer cells communicate and can it help us catch them?Go to article: HOF SonderanlagenbauGo to article: HOF Sonderanlagenbau Company Insight Go to article: Buyers’ clubs: the first step toward universal UK access to Orkambi?Go to article: SterigenicsGo to article: Owen MumfordGo to article: Are we nearing the end of animal testing in pharma?Go to article: Zenatek Go to article: Barc Lab Go to article: A safer ride: the latest innovation in targeted cancer treatment Go to article: Abiogen PharmaGo to article: MimotopesGo to article: Next issue